Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

Highlights

- PS expression on immune cells in murine melanoma is increased after tumor-directed RT
- Blocking PS interaction with its receptors enhances the anti-tumor efficacy of RT
- PD-1 blockade further potentiates the anti-tumor responses
- Melanoma patients’ PBMCs exhibit an increase in PS expression after RT

In Brief

Budhu et al. show that tumor-directed irradiation of murine B16 melanoma causes an increase in PS on the surface of infiltrating immune cells. Blocking PS and RT improves the anti-tumor efficacy and overall survival, which can be further improved with the addition of anti-PD-1. Melanoma patients exhibit increased PS on their PBMCs after RT.

Authors

Sadna Budhu, Rachel Giese, Aditi Gupta, ..., Christopher A. Barker, Jedd D. Wolchok, Taha Merghoub

Correspondence

wolchokj@mskcc.org (J.D.W.), merghout@mskcc.org (T.M.)
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

Sadna Budhu,1 Rachel Giese,1,2 Aditi Gupta,1,3 Kelly Fitzgerald,1,4 Roberta Zappasodi,1,3 Sara Schad,1,3 Daniel Hirschhorn,1 Luis Felipe Campesato,1 Olivier De Henau,1 Mathieu Gigoux,1 Cailian Liu,1 Gregory Mazo,5,6 Liang Deng,1,5,6 Christopher A. Barker,6 Jedd D. Wolchok,1,3,5,7,* and Taha Merghoub1,3,5,7,8,*

1Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
3Weill Cornell Medical College, New York, NY 10065, USA
4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
6Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
7Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
8Lead Contact
*Correspondence: wolchok@mskcc.org (J.D.W.), merghout@mskcc.org (T.M.)
https://doi.org/10.1016/j.celrep.2020.108620

SUMMARY

Phosphatidylserine (PS) is exposed on the surface of apoptotic cells and is known to promote immunosuppressive signals in the tumor microenvironment (TME). Antibodies that block PS interaction with its receptors have been shown to repolarize the TME into a proinflammatory state. Radiation therapy (RT) is an effective focal treatment of isolated solid tumors but is less effective at controlling metastatic cancers. We found that tumor-directed RT caused an increase in expression of PS on the surface of viable immune infiltrates in mouse B16 melanoma. We hypothesize that PS expression on immune cells may provide negative feedback to immune cells in the TME. Treatment with an antibody that targets PS (mch1N11) enhanced the anti-tumor efficacy of tumor-directed RT and improved overall survival. This combination led to an increase in proinflammatory tumor-associated macrophages. The addition of anti-PD-1 to RT and mch1N11 led to even greater anti-tumor efficacy and overall survival. We found increased PS expression on several immune subsets in the blood of patients with metastatic melanoma after receiving tumor-directed RT. These findings highlight the potential of combining PS targeting with RT and PD-1 pathway blockade to improve outcomes in patients with advanced-stage cancers.

INTRODUCTION

Phosphatidylserine (PS) is a phospholipid normally found on the inner leaflet of the plasma membrane in healthy cells. Upon activation of certain downstream signals (e.g., caspase-3/7), enzymes such as scramblases can collapse the polarized distribution of PS, causing accumulation on the outer membrane (Birge et al., 2016). Cell surface expression of PS is classically thought to be exclusive to apoptotic cells, in which externalized PS acts as an “eat me” signal for PS receptors expressed on macrophages and promotes clearance of apoptotic debris (effrocytosis). This process has been shown to be immunosuppressive in tissues because of attenuation of dendritic cell (DC) and natural killer (NK) cell activation and conversion of tumor-associated macrophages (TAMs) into anti-inflammatory or M2 macrophages (Graham et al., 2014; Kumar et al., 2017). Numerous PS receptors are ubiquitously expressed on immune cells. Among these are immunosuppressive receptors that belong to the Axl/Mer/Tyro3 receptor tyrosine kinase family, T cell immunoglobulin mucin domain (TIM) receptors, integrins, and the scavenger receptor family (Birge et al., 2016; Graham et al., 2014). Although some receptors directly bind to PS, other require an adaptor protein (e.g., GAS6) to bridge PS with its receptors.

PS can also be expressed on the surface of viable cells. PS is externalized on activated platelets, monocytes, mature macrophages, activated B cells, activated T cells, DCs, tumor vasculature, tumor cells, and the surface of exosomes derived from tumors (Birge et al., 2016). PS exposure on viable cells does not induce phagocytosis, because phagocytes are able to distinguish PS on viable versus apoptotic cells. The exact mechanism of this phenomenon remains unknown; however, PS exposure on apoptotic cells is caspase-3/7 dependent with slow kinetics (in hours) and is irreversible, whereas PS exposure on viable cells
is thought to depend on intracellular Ca\(^{2+}\) with more rapid kinetics (in minutes) and is reversible (Birge et al., 2016). In addition, the density and spatial distribution of PS on the cell surface may dictate how phagocytic cells and their receptors distinguish dying from viable cells.

Several strategies have been developed to block PS interaction with its receptors (Belzile et al., 2018; Kumar et al., 2017; Sharma and Kanwar, 2018). These include an annexin V fusion protein, blocking antibodies that target PS and inhibitors of PS receptors. Monoclonal antibodies that block PS interactions with its receptors have demonstrated anti-tumor activity in mouse tumor models (He et al., 2009; Huang et al., 2005; Ran et al., 2005; Yin et al., 2013). These antibodies exert their anti-tumor effects through destruction of the tumor vasculature (He et al., 2009; Ran et al., 2005). In addition, they repolarized TAMs into a proinflammatory M1 phenotype, reduce the number of myeloid-derived suppressor cells (MDSCs) in tumors, and promote the maturation of DCs into functional antigen-presenting cells (APCs). In syngeneic mouse models of breast cancer and melanoma, targeting PS using the mouse monoclonal antibody mch1N11, which blocks the interaction of PS with its receptors, in combination with immune checkpoint blockade (ICB) promoted greater anti-tumor activity than either agent alone (Freimark et al., 2016; Gray et al., 2016).

Radiation therapy (RT) is commonly used for the treatment of cancer. The abscopal effect, a phenomenon in which tumor-directed radiation is associated with the regression at a distal site, has been observed with RT. However, the frequency of this occurrence is exceedingly low (Siva et al., 2015). RT can induce immunogenic tumor cell death, leading to efficient priming of tumor-antigen-specific T cell responses (Apetoh et al., 2002; Panaretakis et al., 2009). RT can also induce expression of proteins such as major histocompatibility complex (MHC) class I and intercellular adhesion molecule 1 (ICAM-1), which allows antigens presented by tumor cells to be better recognized, leading to more efficient elimination by cytotoxic T cells (Gameiro et al., 2014). CD8+ T cells appear to be essential for the anti-tumor effects of RT (Chen et al., 2018; Gupta et al., 2012; Lee et al., 2009). When CD8+ T cells were depleted using monoclonal antibodies, there was an abrogation of the anti-tumor responses of RT (Gupta et al., 2012; Rodriguez-Ruiz et al., 2016). In addition, RT is associated with increased activation and infiltration of CD8+ T cells in tumors. This effect depends on type I interferons (IFNs) and is associated with the activation and recruitment of cross-presenting/Batf3-dependent DCs (Rodriguez-Ruiz et al., 2016; Vanpouille-Box et al., 2017).

Tumor-directed RT can enhance ICB by overcoming some resistance mechanisms associated with ICB. It can turn a poorly infiltrated “cold” tumor into a highly infiltrated “hot” tumor. Tumor-directed RT may act as an in situ vaccine, triggering activation of tumor-antigen-specific T cells (Lugade et al., 2005). It can also recruit activated CD4+ and CD8+ effector T cells to the tumor site via the release of chemokines and upregulation of adhesion molecules in tumor vasculature (Lugade et al., 2005; Matsumura et al., 2008). Several clinical reports on the abscopal effect in melanoma patients who received immunotherapy and tumor-directed RT have renewed interest in RT as a means to potentiate the efficacy of ICB (Golden et al., 2013; Hiniker et al., 2012; Okwan-Duodu et al., 2015; Postow et al., 2012; Stammel et al., 2013).

In this study, we show that PS expression on immune cells infiltrating mouse B16 melanoma was increased after a single dose of tumor-directed RT. We blocked PS signaling using the monoclonal antibody mch1N11 and showed that it enhanced the anti-tumor efficacy of tumor-directed RT. This combination enhanced priming of tumor-antigen-specific T cells and their recruitment to the tumor. In addition, there was a repolarization of the tumor microenvironment (TME) from an anti- to a proinflammatory state with the combination therapy. When ICB (anti-program cell death protein 1 [anti-PD-1]) was added to the combination of RT and PS blockade, there was an even greater delay of tumor growth and overall survival. This triple-combination therapy induced potent activation of cytotoxic CD8+ T cells in the tumor and the periphery, leading to enhanced abscopal responses in a contralateral (non-irradiated) tumor model. In agreement with the mouse studies, we show that immune subsets in the peripheral blood of melanoma patients exhibited an increase of PS expression 4–7 days after tumor-directed RT.

RESULTS

PS Expression on Immune Cell Subsets Increases after RT in the TME

We sought to carefully examine PS expression on immune cells in the TME. C57BL/6 mice were implanted with B16 melanoma cells intradermally, and tumors were harvested 10 days later to examine PS expression by flow cytometry. Because annexin V is commonly used to label PS on apoptotic cells, we co-stained for caspase-3/7 activity and a viability dye to distinguish PS expression on viable cells from apoptotic and dead cells (Figure 1A). Annexin V staining was compared with a PS antibody, which showed similar staining patterns on immune cells; however, annexin V staining exhibited better resolution than the PS antibody (Figure S1A). When gated on viable immune cells in the tumor, the annexin V+ single-positive cells are distinct from caspase-3/7+ or apoptotic cells (Figure 1B). Many viable immune cell subsets in the tumor express PS on their surface (Figure 1C). This expression pattern varied considerably on different immune cell types, with myeloid cells expressing the highest amounts of PS. The expression pattern of PS on immune subsets in the tumor was confirmed using an anti-PS antibody (Figure S1B). Because RT is known to directly induce immunogenic cell death within the TME, we hypothesized that RT may increase cell surface PS expression on both tumor cells and immune infiltrates. To test this, we examined the expression of PS on these cells after tumor-directed RT. The right hindlimbs of C57BL/6 mice were implanted with B16 melanoma cells, and 10 days later, they were irradiated with a single dose of 15 Gy (Figure 1, schema). This dose and schedule of radiation were previously determined to exhibit optimal immune-stimulatory activity against B16 melanoma in vivo (Lugade et al., 2005). Tumors were excised 1, 5, and 10 days after RT and examined for expression of PS. No significant changes in frequencies or PS expression were observed on immune subsets at early time points (1 and 5 days post-RT) (Figure S1C). However, there
was a marked increase in CD8+ T cells coupled with a decrease in myeloid cells 10 days after RT (Figure 1D). PS expression, on immune cells devoid of caspase activity, was increased 10 days after RT on nearly all cell types present in the tumor, with the greatest increase seen on the myeloid cells and the tumor cells (Figure 1E). Because RT is known to ablate immune cells in the TME, the observation that it takes 10 days to see an increase in PS expression may reflect the time it takes for these cells to be primed in the secondary lymphoid organs and then migrate to and repopulate the tumor. We also observed that B16F10 cells, when treated with 15 Gy RT in vitro, upregulated surface expression of PS within 24 h, demonstrating a direct effect of RT on PS expression on tumor cells (Figure S1D). This effect is enhanced with the addition of cytokines such as IFNγ to the culture. Because CD8+ T cells are a source for proinflammatory cytokines such as IFNγ, we asked whether CD8+ T cells were necessary for the increase in PS expression in the TME. We depleted CD8+ T cells using a depleting antibody (clone 2.43) starting the same day as RT and examined the expression PS in the TME 10 days later. Depletion was confirmed in the tumors on day 10 by flow cytometry (Figure S1E). CD8-depleted mice showed significantly diminished PS staining (annexin V+) on...
immune cells in the tumors 10 days after RT (Figure S1F). Tumor-directed RT is known to activate the c-GAS/Sting pathway, leading to the secretion of type I IFNs and maturation of DCs (Diamond et al., 2018). We tested whether the cyclic GMP-AMP Synthase (c-GAS)/Sting pathway was involved in the upregulation of PS using Sting−/− C0 B16F10 cells and StingGt/Gt C57BL/6 mice (Sauer et al., 2011). The c-GAS/Sting pathway does not appear to be necessary for the observed increase in PS expression, because PS is significantly increased on immune cells in the TME of StingGt/Gt mice (Figure S1F). These results indicate that CD8+ T cells are partly responsible for the increase of PS expression on immune cells after RT. In addition, we observed similar increases in PS expression, albeit to a lesser extent, on immune subsets in the spleen at 10 days (but not 1 or 5 days) after RT, suggesting that this effect was systemic (Figure S1G).

**Targeting PS in Combination with Tumor-Directed RT Enhances Anti-tumor Efficacy in B16 Melanoma**

The finding that PS expression increased after RT in the TME suggests that PS may provide an inhibitory signal to immune cells that limits the immune-mediated anti-tumor efficacy of PS-targeting antibody 1N11 (Mineo et al., 2016). This antibody does not directly bind PS but rather blocks its interaction with PS receptors (Belzile et al., 2018). We treated mice bearing B16 melanoma with a single dose of 15 Gy RT 10 days after implantation, and 1 day following RT, mice received mch1N11 (200 μg/mouse) via intraperitoneal (i.p.) injection, followed by a second dose 3 days later (Figure 2, schema). A single dose of 15 Gy was effective at controlling B16 tumor growth for approximately 2 weeks, after which 90% of tumors begin to regrow (Figure 2A). Treatment with mch1N11 alone had no significant effect on B16 tumor growth. However, there was greater anti-tumor efficacy in the animals treated with mch1N11 and RT, a setting in which 40% of the mice demonstrated complete regression of tumors. This combination led to significantly longer overall survival, with a median survival of 65 days with the combination versus 57 days with RT alone (Figures 2B and 2C).

**Targeting PS with mch1N11 Promotes M1 Macrophage Polarization In Vitro and In Vivo**

A PS-targeting antibody similar to mch1N11 has been previously shown to repolarize TAMs toward a proinflammatory M1 phenotype (Yin et al., 2013). We cultured bone-marrow-
derived macrophages (BMDMs) in the presence of mch1N11 or an isotype-matched control (C44) for 24 h to examine whether this antibody can promote proinflammatory macrophages in vitro. The culture conditions to derive BMDMs generated primarily macrophages (CD11b+ F4/80+ cells), which were the dominant cell population expressing PS (Figure 3A). Using the mannose receptor (CD206) and MHC class II expression to distinguish between M1 and M2 macrophages (Figure 3B), we found that mch1N11 decreased M2 macrophages (CD206+ MHC II−) and increased M1 macrophages (CD206− MHC II+) after 24 h in culture (Figure 3C). This led to a favorable skewing of the M1/M2 macrophage ratio, shifting the macrophage polarization to a proinflammatory phenotype. We next determined whether mch1N11 in combination with RT can repolarize TAMs in vivo. At an early time point (3 days post-treatment), there were no differences in the total TAM population or their polarization status in the treated groups (Figure 3D). At 10 days post-treatment, there was a significant increase in the frequency of TAMs in the tumors treated with RT or the combination with mch1N11. This increase appears to mainly result from RT alone. In addition, we observed a significant decrease in M2 macrophages and a corresponding increase in M1 macrophages in the combination treatment group. This resulted in an ~15-fold increase in the M1/M2 macrophage ratio in the tumor, significantly shifting the TAMs toward a proinflammatory phenotype (Figure 3E). In addition, we examined

Figure 3. Targeting PS with mch1N11 Promotes a Proinflammatory TME

(A–C) Bone marrow (BM) from naive C57BL/6 mice was isolated and cultured in the presence of 20 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF). 6 days after culture, BM cells were isolated and replated in 12-well plates in the presence or absence of a control isotype (C44) or PS-targeting antibody (mch1N11). 24 h later, cells were detached and analyzed by flow cytometry for APCs (CD11c+ MHC II+), total macrophages (CD11b+ F4/80+), M1 macrophages (MHC II+ CD206−), and M2 macrophages (MHC II− CD206+). (A) Left: abundance of macrophages, APCs, and granulocytes in the BM cultures after 6 days. Right: expression of PS on the surface of each cell type as measured by annexin V staining on live cells. (B) Gating strategy used to identify M1 and M2 macrophages. (C) Quantification of M1 and M2 macrophages ± SEM pooled from 3 experiments.

(D–E) C57BL/6 mice were injected with B16F10 melanoma cells and treated according to the experiment outlined in Figures 2 and here. 10 days after the initial treatment, tumors were isolated from each treatment group and analyzed by flow cytometry. With 3–5 mice per group, statistics were calculated using two-way ANOVA corrected for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.005.

(F) Tumors were harvested 3 days after initial treatment. RNA was extracted from whole tumors and analyzed for expression of 43 preselected genes (Table S1) using the Fluidigm Biomark MX/HD system, as described in STAR Methods. Gene expression data are represented as the average fold change (2^{ΔΔCt}) relative to the control group versus the calculated p values to represent significant increase (>1 fold change and p > 0.05, blue circles) and decrease (<1 fold change and p > 0.05, red circles) in gene expression.
Figure 4. Targeting PS Enhances Antigen-Specific T Cell Priming in Response to RT

(A) C57BL/6 mice were injected with B16F10 melanoma cells and treated according to the experiment schema in Figure 2. 10 days after the initial treatment, tumor-draining LNs were isolated and analyzed by flow cytometry. Plotted are the frequencies of effector memory (CD44+ CD62L−) and granzyme B+ cells as a percentage of the total CD4+ and CD8+ T cell populations ±SEM (3–5 mice/group).

(B) Experimental schema:

(C) (D) (E)
the frequencies of total APCs, which are phenotypically defined as CD11c+ MHC II+ cells and therefore represent a mixture of both TAMs and DCs, because subsets of both of these cell types express CD11c and MHC class II. We found an early increase in the frequencies of APCs that is only observed in the RT groups. However, no significant changes in APCs were observed at later time points (Figures 3D and 3E). These data suggest that the combination of RT and mch1N11 exerts its effects on TAMS, but not on other populations of APCs.

Targeting PS in Combination with RT Promotes an Increase in Proinflammatory Cytokine Gene Expression and a Corresponding Decrease in Anti-inflammatory Genes

To better understand the effects of RT and mch1N11 on the TME, we isolated RNA from whole tumors 4 days after treatment and analyzed the expression of a preselected list of pro- and anti-inflammatory genes (Table S1). mch1N11 treatment alone showed a decrease in many pro- and anti-inflammatory genes, whereas RT alone led to an increase in expression of many proinflammatory cytokines (Figure 3F; Figure S2). The combination of RT and mch1N11 not only significantly increased expression of many proinflammatory cytokines but also decreased expression of anti-inflammatory markers such as CD206, transforming growth factor β (TGF-β), arginase 1, Foxp3, and interleukin (IL) 4-RFα (Figure 3F; Figure S2). When compared with RT alone, 2 genes—IL-2 and IFNγ—were significantly upregulated in the combination treatment group. These data suggest that RT alone and in combination with mch1N11 alter the transcriptional profile of cells in the TME to a proinflammatory microenvironment, with changes in both innate and adaptive immunity.

Targeting PS Enhances Tumor-Antigen-Specific T Cell Priming in Response to RT

RT has been shown to prime and recruit CD8+ T cells to tumors (Chen et al., 2018; Gupta et al., 2012; Lugade et al., 2005). The finding that the combination therapy repolarizes TAMs to become proinflammatory suggests that the TME is now more permissive to priming and activation of tumor-specific T cells. We investigated whether targeting PS in combination with tumor-directed RT had a systemic effect on T cell activation. We analyzed CD4+ and CD8+ T cells in the draining lymph nodes (LNs) 10 days after initial treatment. We found an increase in T cell activation markers such as Ki67 and CD25 in both CD4+ and CD8+ T cells (Figure S3A) and a significant increase in effector memory T cells (Figure 4A) in the combination treatment group. In addition, T cells in the combination group had higher expression of effector molecules, such as the cytolytic enzyme granzyme B and the proinflammatory cytokines IFNγ and tumor necrosis factor alpha (TNFα) (Figure 4A; Figure S3A). This led us to postulate that the combination of RT and mch1N11 leads to T cell priming in the draining LNs and spleen. To test this more definitively, we examined whether this therapy can enhance the priming of tumor-antigen-specific CD8+ T cells and their recruitment to the tumor site. We isolated naive CD8+ T cells from a transgenic mouse whose T cell receptor (TCR) specifically recognized a melanoma differentiation antigen gp100 (or Pmel-1), which is a tumor antigen in the case of melanoma (Overwijk et al., 2003). We adoptively transferred carboxyfluorescein succinimidyl ester (CFSE)-labeled naive tumor-antigen-specific Pmel CD8+ T cells into tumor-bearing animals treated with RT alone or RT in combination with mch1N11. Pmel CD8+ T cells were transferred on the same day as RT treatment, and the animals were given two doses of mch1N11 (Figure 4B, schema). Seven days following RT, blood, spleen, tumor-draining LNs, and tumors from the treated animals were isolated and analyzed for priming and activation of transferred Pmel CD8+ T cells. The congenic marker Thy1.1 expressed by Pmel CD8+ T cells was used to distinguish the transferred cells (Thy1.1+) from the endogenous CD8+ T cells (Thy1.1−) in these tissues (Figure 4B). The combination of RT with mch1N11 significantly increased the frequency of tumor-antigen-specific T cells in all tissues (Figure 4C). Tumor-bearing mice that were untreated or treated with mch1N11 without RT were inefficient in priming Pmel CD8+ T cells (Figure 4C; data not shown). The transferred Pmel T cells proliferated efficiently (as measured by CFSE dilution) in response to RT and the combination treatment, with the greatest effects seen in tumor-draining LNs and tumors (Figures 4D and 4E). The numbers of transferred cells were relatively low in some tissues, making it difficult to analyze their activation status with statistical power. However, we did observe an overall increase in central memory and effector memory T cells, as well as an increase in PS expression on the surface of transferred T cells in all tissues examined in response to both RT and the combination (Figure S3B). In addition, examination of the endogenous CD8+ T cells in these tissues showed an increase in central memory and effector memory T cells and in surface PS expression, suggesting that there was effective priming of endogenous T cells in response to RT and the combination treatment (Figure S3B).

Anti-PD-1 Enhances the Anti-tumor Efficacy of RT and mch1N11

Because of the clinical success of immunotherapies targeting T cell checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), PD-1 and its ligand (PD-L1), ICB is now a commonly used cancer treatment and the focus of clinical research. We asked whether ICB could enhance the therapeutic efficacy of the combination treatment and examined the effects of combining tumor-directed RT with mch1N11 and anti-PD-1. Our rationale for combining anti-PD-1 with RT and mch1N11 is 2-fold. First, we and others have observed that PD-L1...
expression is increased on the surface of tumor cells after RT (Deng et al., 2014; Twyman-Saint Victor et al., 2015). We also found that PD-1 expression is increased on tumor-infiltrating CD8+ T cells with the combination of RT and anti-PS (Figure S3B). Therefore, because the ligand and receptor are present in the TME, activation of the PD-1/PD-L1 axis in T cells may limit the effectiveness of RT and mch1N11. Second, when thinking of the feasibility of translating our findings to the clinic, we must...
Figure 6. Targeting PS in Combination with Radiation Therapy and Anti-PD-1 Promotes CD8+ T Cell Activation in the Tumor

(A) C57BL/6 mice were injected with B16F10 cells and treated according to the experiment schema outlined in Figure 5. 10 days after RT, 10^6 CD8+ T cells purified from spleens of treated animals were co-cultured with 10^4 B16 tumor cells as targets for 48 h in 24-well plates for a T cell killing assay as previously described (Budhu et al., 2010). Shown are the average percentage ± SEM of B16 cells killed from 5 mice/group.

(B) C57BL/6 mice were injected with B16F10 cells on the right hindlimb on day 0 and left flank on day 5 and treated with RT on day 10, as outlined in the schema and described in STAR Methods. Shown are average tumor size (in square millimeters) ± SEM of abscopal tumors only (10 mice/group). Statistics were calculated at day 25 post-tumor implantation.
consider that PD-(L)1 blockade is becoming a standard approach for the treatment of various cancers, including melanoma. It would be challenging to design a clinical trial in which patients that are naïve to immunotherapy can realistically be accrued with an experimental drug (e.g., bavituximab, the clinical equivalent of mch1N11) in lieu of anti-PD-(L)1. In our experimental setting (Figure 5, schema), anti-PD-1 is given using a suboptimal schedule, which shows a modest delay in tumor growth, and only ~10% of the animals have complete tumor regression (Figures 5A and 5B). Treatment of anti-PD-1 with mch1N11 further delayed tumor progression; however, the combination of these two agents with RT showed the greatest anti-tumor efficacy and overall survival (Figure 5). In the triple combination, 60% of the animals had complete regression of tumors compared with 30% with RT and mch1N11 and 40% with RT and anti-PD-1 (Figures 5A and 5B). In addition, median survival for the triple-combination group was >80 days compared with 65 days in the RT and mch1N11 or RT and anti-PD-1 groups (Figure 5C). These data suggest that adding RT with a clinical PS-targeting agent (e.g., bavituximab) could potentially enhance clinical outcomes. The c-GAS/Sting pathway has been linked the anti-tumor response to RT (Diamond et al., 2018; Formenti et al., 2018). We explored the role of this pathway in the triple-combination therapy using Sting<sup>KO</sup> B16F10 cells and Sting knockout (KO) mice (Sting<sup>GZ/GZ</sup>). Activation of the Sting pathway may be important for the anti-tumor efficacy of RT alone, because tumor growth control and median survival appear to be lower in the Sting<sup>GZ/GZ</sup> mice (Figure S4A). However, activation of the c-GAS/Sting pathway appears to be dispensable for the triple-combination therapy, in which tumor growth control, median survival, and overall survival do not appear to be significantly different in the wild-type (WT) versus KO groups.

We examined whether the triple-combination therapy can also be effective in a non-melanoma model. MC38 colon carcinoma is considered more immunogenic and more responsive to anti-PD-1 than B16 melanoma. C57BL/6 mice were implanted subcutaneously on the right hindlimb with MC38 cells, and tumors were treated with the same antibody dose and schedule as in the B16 experiments. We found that the therapies without radiation (anti-PD-1 alone and mch1N11 + anti-PD-1) showed similar results in delaying MC38 tumor growth when compared with B16 melanoma (Figure S4B versus Figures 5A and 5B). However, the overall survival was better in the combination of mch1N11 and anti-PD-1 for MC38 (Figure S4B). The addition of RT led to potent anti-tumor responses and overall survival in all RT groups, and 78%–100% of the mice had complete tumor regression. To determine whether these treatments conferred long-term immunity in the cured animals, we reimplanted 500,000 MC38 cells on the right flank 100 days after the first treatment. All cured animals were able to delay the secondary rechallenge equally, with an average of 40% of all treated groups (and 34% of the RT groups) remaining tumor free (Figure S4C).

**Targeting PS in Combination with RT and Anti-PD-1 Promotes CD8<sup>+</sup> T Cell Activation**

A stringent test of any therapy that involves tumor-directed treatment (such as RT) is whether it can induce a systemic immune response. CD4<sup>+</sup> and CD8<sup>+</sup> T cells from the spleen and draining LNs of treated animals showed an increase in T cell activation markers such as Ki67 and granzyme B, with the greatest effects generally seen using the triple combination (Figures SSA and SSB). There were no changes in CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Tregs) observed in the periphery. Recently, we described a suppressive population of CD4<sup>+</sup> T cells that do not express the transcription factor Foxp3 but express high levels of PD-1 (Zappasodi et al., 2018a). We found that these CD4<sup>+</sup>Foxp3<sup>+</sup>PD-1<sup>H</sup> (PD-1<sup>H</sup>) T cells are decreased in the spleen and LNs, leading to a corresponding increase in the ratio of CD8 and CD4 to PD-1<sup>H</sup> cells in both tissues (Figures S5C and S5D). In addition, we purified CD8<sup>+</sup> T cells from the spleens of treated animals and conducted an ex vivo T cell killing assay using B16 cells as targets. We found that CD8<sup>+</sup> T cells killed B16 tumor cells most efficiently in conditions in which mch1N11 was added to RT and/or anti-PD-1 (Figure 6A). Thus, it appears that treatment with mch1N11 promotes cytolytic T cells systemically. These data demonstrate that this triple-combination therapy induces a strong systemic immune response that may be capable of controlling distant tumors or metastases. Using a bilateral tumor model, we examined the effect of combining RT with mch1N11 and anti-PD-1 on secondary non-irradiated (abscopal) tumors (Figure 6B, schema). The combination of RT and anti-PD-1 and the triple combination of RT, mch1N11, and anti-PD-1 significantly reduced the growth of the secondary non-irradiated tumors, suggesting that these treatment regimens induce potent systemic anti-tumor responses (Figure 6B).

The observation that the triple combination of RT, mch1N11 and anti-PD-1 produced the most effective anti-tumor responses and overall survival prompted us to determine the impact of each of these therapies alone or in combination on the immune responses in the tumor. 10 days after treatment, anti-PD-1 alone or in combination with mch1N11 increased CD8<sup>+</sup> T cell infiltration in the tumors from ~18% to ~40% of the total immune infiltrates within the treated tumors (Figure 6C). When RT was added, there was a greater increase in CD8<sup>+</sup> T cell infiltration in the tumor with RT alone or in combination with mch1N11 and/or anti-PD-1. In all RT groups, the increase in CD8<sup>+</sup> T cells accounted for ~60% of all immune cells (CD45<sup>+</sup> cells) present in the tumor. The frequency of CD8<sup>+</sup> T cells (relative to the total immune infiltrates in the tumor) had a strong inverse correlation with the tumor weight in all groups (Figure 6C). Moreover, the CD8<sup>+</sup> T cells in the tumors were qualitatively different in each treatment group. In all groups that received tumor-directed RT, CD8<sup>+</sup> T cells displayed increased expression of activation markers such as Ki67 and the transcription factor Tbet (Figure 6C). This effect was also observed in the combination of mch1N11 and anti-PD-1 without RT. In addition, there was an increase in CD8<sup>+</sup> T cell expression of granzyme B.
in the combinations that included mch1N11 and anti-PD-1 (±RT). These T cell activation markers correlated inversely with tumor size, with the strongest correlation seen in the Tbet+ CD8+ T cells (Figure 6C). We also observed an increase in PD-1+ CD8+ T cells in all RT groups. These PD-1+ cells co-express granzyme B and Ki67, suggesting these are activated effector CD8+ T cells (Figure S8). Although CD8+ T cells appeared to be optimally activated in the RT tumors, there was still a significant increase in activated CD8+ T cells in the combination of mch1N11 and anti-PD-1 without RT (Figure 6C). This combination also led to significant anti-tumor activity in the absence of RT (Figures 5B and 5C). We also observed a decrease in CD4+ Foxp3+ Tregs in the tumors from the RT-treated groups. This corresponded to an increase in the CD8:Treg ratio, with the strongest effect seen in the triple-combination therapy group (Figure 6D). We found that 4PD-1+ T cells are decreased after RT, with the greatest decrease observed in the triple combination (Figure 6D). In addition, the ratio of CD8 to 4PD-1+ cells was significantly increased in the RT groups, with the triple combination showing the highest increase. None of the treatments had a significant effect on effector (Foxp3− PD-1low) CD4+ T cell infiltration or their activation state in the tumor (data not shown).

Peripheral Blood Mononuclear Cells (PBMCs) from Melanoma Patients Demonstrated an Increase in PS Expression on Immune Subsets 4–7 Days after Tumor-Directed RT

To determine whether these preclinical findings have relevance in a clinical setting, we examined PS expression on immune subsets in the blood of melanoma patients receiving RT. Peripheral blood was collected from 7 melanoma patients before and 4–7 days after receiving tumor-directed RT to one or more metastases. Freshly isolated PBMCs from each patient were stained for PS expression using annexin V, caspase-3/7, and known lineage markers for human immune subsets on the same day the blood was collected (Figures 7A and 7B; Figure S7A). Annexin V staining of PS on viable cells was confirmed with an anti-PS antibody, which showed similar staining patterns (Figure S7B). We found that PS expression on several immune subsets increased after RT in 6 of 7 patients tested (Figure 7C). The most significant increases were seen in CD14+CD11b+ myeloid cells, CD56int NK cells, and CD8+ T cells, consistent with the findings in mouse studies (Figure 1E). PD-1 expression was also examined on each immune subset; however, it did not significantly change or correlate with PS expression at the time points examined, suggesting that the mechanisms and kinetics involved in regulating expression of PS are distinct from those for PD-1 (Figure S7C; data not shown). We were able to collect PBMCs before and 4 and 31 days after receiving tumor-directed RT from a single patient (Pt. 6). The increase in PS expression observed early (4 days) after RT was transient and returned to normal after 31 days (Figure S7D).

**DISCUSSION**

An interesting observation from this study is the finding that PS is expressed on viable immune cells in the TME. Other studies have also shown that PS is expressed on activated immune cells and the kinetics are different from apoptotic cells (Birge et al., 2016). For example, PS expression on viable cells depends on intracellular Ca2+. Because the activation of T cells through TCR stimulation increases intracellular Ca2+, it is not surprising that PS expression is increased on activated T cells. In addition, the density and spatial distribution of PS on the cell surface of viable and apoptotic cells may differ (Birge et al., 2016; Kumar et al., 2017). It will be interesting in the future to delineate the transcriptional and functional profile of immune cells that express PS on their surface compared with those that do not. We posit that PS acts similarly to an immune checkpoint molecule on viable immune cells in which it is induced during activation and acts as a negative feedback mechanism to prevent aberrant activation of the immune system. Thus, similar to blocking immune checkpoints, blocking PS removes this feedback, allowing more potent activation of both innate and adaptive immune cells. However, removing this suppression is not sufficient to promote anti-tumor immunity, because mch1N11 as a single agent is ineffective in controlling B16 tumor growth. Additional proinflammatory signals are required to prime and boost the immune responses to the tumor. RT and PD-1 blockade can each provide these additional proinflammatory signals.

A remaining unknown is the mechanism by which PS expression is increased after RT. It appears that PS expression is highest in the tumor when inflammation in the TME is highest (10 days post-RT). This would suggest that PS expression correlates with immune cell activation. Although we observed the highest increase in PS expression on immune cells in the tumors, this effect was also seen in the spleen of treated mice and in the blood of melanoma patients receiving tumor-directed RT. This suggests a possible role for secreted or soluble factors such as cytokines. RT has also been shown to induce the secretion of multiple cytokines that recruit immune cells to the tumor site (Barker et al., 2018; Matsumura et al., 2008). Consistent with this, our results indicate that CD8+ T cells are partially responsible for the increase in PS expression on immune cells in the tumors after RT. Activated CD8+ T cells are the main producers of proinflammatory cytokines such as IFNγ in the TME and are therefore most likely responsible for the increase in PS expression in the TME. In agreement with this, we showed that cytokines such as IFNγ can increase PS expression on tumor cells in vitro (Figure S1D).

There is an abundance of PS receptors on the surface of immune cells. Members of the Axl/Mer/Tyro3 receptor tyrosine kinase family have been largely implicated in the clearance of apoptotic cells expressing PS (efferocytosis). However, the specific receptor or receptors recognizing PS on viable immune cells remains unknown. The antibody used in our studies, mch1N11, does not directly bind to PS but rather binds to the adaptor protein j2-glycoprotein I (j2GPI) and blocks its interaction with PS receptors (Bezile et al., 2018). Initial studies show that j2GPI is important for the activity of PS-targeting antibodies such as mch1N11 (Ran et al., 2005). For the in vitro studies reported here (Figure 3C), mouse serum needed to be added to the culture to provide a source for j2GPI to efficiently block PS interaction with its receptors. The exact receptor that binds j2GPI-bound PS remains unknown. However, several receptors, including members of the Toll-like receptor (TLR) family
Figure 7. Melanoma Patients Demonstrated an Overall Increase of PS Expression on Immune Subsets in the Blood 4–7 Days after RT
Peripheral blood was collected from 7 melanoma patients before and 4–7 days after receiving tumor-directed RT. Freshly isolated PBMCs from each patient were stained for PS expression using annexin V on the day the blood was collected, as described in STAR Methods.

(A) Histogram plots of annexin V staining of viable immune cell subsets in PBMCs from a single patient (Pt. 1) pretreatment (Tx) and post-RT.

(B) Representative plots gated on live CD3+ CD8+ T cells of annexin V versus caspase-3/7 activity of PBMCs from a single patient pre-RT and 4 days post-RT. FMO, control.

(C) Top: individual values for each patient. Bottom: average percentage ± SEM of annexin V+ immune cell subsets pre-RT and post-RT. *p < 0.05, ***p < 0.005.

(D) Model summarizing the effects of targeting PS with RT and anti-PD-1 on immune cell activation.
(TLR2, TLR4, and TLR8), annexin A2, glycoprotein Ibα, and low-density lipoprotein (LDL)-receptor family-related protein (LRP) 8, also known as ApoER2, have been reported to interact with β2GPI-antibody complexes (de Groot and Urbanus, 2012). It will be interesting to decipher which PS receptor or receptors play a role in promoting an anti-inflammatory TME and which receptors are affected by mch1N11-mediated blocking of PS-β2GPI interactions.

We show that blocking PS signaling through its receptors with mch1N11 enhances local and systemic CD8+ T cell activation and, to a lesser extent, CD4+ T cell activation when combined with RT and/or PD-1 blockade (Figures 4A and 6C). In our experiments, we observed increased PS expression of adoptively transferred antigen-specific Pmel and endogenous CD8+ T cells in mice treated with RT + mch1N11 (Figure S3B). These transferred cells also show increased expression of memory and activation markers, indicating that PS expression is associated with activated effector T cells. This is consistent with previous reports that PS is externalized on the surface of activated T cells (Birge et al., 2016). In addition, the data from the experiments in Figures 4A and 6C show that the combination of mch1N11 with RT and/or anti-PD-1 enhances CD8+ T cell expression of the cytolytic protein granzyme B. We also observed enhanced CD8+ T cell-mediated killing of B16 tumor cells when mch1N11 is combined with RT and/or anti-PD-1 (Figure 6A). These data suggest that the addition of mch1N11 to RT or anti-PD-1 promotes a cytolytic program in CD8+ T cells, and this may be the main mechanism by which mch1N11 enhances the anti-tumor efficacy of RT with or without anti-PD-1. Whether blocking the PS interaction with its receptors can alter T cell directly or affect T cell activation and cytolytic programming by repolarizing the TME toward a proinflammatory environment remains an open question.

We summarized the various effects of the combination of mch1N11 with RT and anti-PD-1 on the immune system in Figure 7D. We propose that each therapy (mch1N11, RT, and anti-PD-1) has a unique mode of action and that when combined, this leads to potent activation of the immune system. In untreated animals, B16 tumors express basal levels PS on the cell surface of viable tumor and immune cells. In addition, the TAMs have an anti-inflammatory M2 phenotype and the CD8+ T cells are dysfunctional (Figure 7D, first row). Tumor-directed RT kills a fraction of tumor cells and increases PS expression on the remaining viable tumor cells and immune cells. In addition, there is a slight increase in CD8+ T cell infiltration and activation; however, the TAMs remain relatively unchanged (Figure 7D, second row). When RT is combined with mch1N11, there is an increase in CD8+ T cell infiltration and activation and proinflammatory M1 macrophages (Figure 7D, third row). The addition of anti-PD-1 to RT and mch1N11 increases the infiltration and significantly enhances the activation state of CD8+ T cells (Figure 7D, last row). The resulting effect of the triple-combination therapy is a potent activation of both the adaptive and the innate arms of the immune system.

The therapeutic success of ICB in a subset of cancer patients has brought immunotherapy to the spotlight for further research. However, the clinical success rate of approved ICB as monotherapy remains relatively low, with 20%–40% of patients showing durable clinical responses (Zappasodi et al., 2018b). Several mechanisms of resistance have been identified that limit the efficacy ICB. Hence, there is an unmet need for new therapies to overcome these resistance mechanisms in patients. We believe that the combination of RT and PS blockade could not only make an immunologically cold tumor hot but also alleviate the suppressive mechanisms that exist in the TME. In this sense, the combination of RT and PS blockade can enhance the efficacy of ICB. The finding that melanoma patients showed an increase of PS expression on immune subsets in the blood 4–7 days after tumor-directed RT suggests that the mouse and human biology, in this respect, are similar. The clinical PS-targeting equivalent of the mouse mch1N11, bavituximab, has been used in patients and was well tolerated at doses ranging up to 3 mg/kg weekly (Gerber et al., 2011). The vast preclinical data and patient data reported here highlight the potential of using tumor-directed RT with a PS-targeting agent to enhance the clinical outcome of patients being treated with anti-PD-1. We rationalize that the patient population that would most likely benefit from novel combination therapies such as RT and PS blockade includes those who were previously treated with anti-PD-1 and did not respond or became refractory to the therapy.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mouse Models
  - Cell lines
  - Patient Material
- METHOD DETAILS
  - In vivo mouse experiments with tumor-directed RT and monoclonal antibody treatment
  - Gene expression in ex vivo tumors
  - Adoptive transfer of Pmel CD8+ T cells
  - In vitro macrophage polarization
  - Flow Cytometry of mouse LNs, spleens, and tumors
  - Annexin V and Caspase 3/7 staining of mouse tissues
  - Annexin staining of melanoma patients PBMCs
  - CD8+ T cell killing assay
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.108620.

ACKNOWLEDGMENTS

This research was funded partly through NIH/NCI Cancer Center support grant P30 CA006748, NIH/NCI R01 CA056821, the Swim Across America, Ludwig
Institute for Cancer Research, Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering, Cancer Research Institute, Parker Institute for Cancer Immunotherapy, and Breast Cancer Research Foundation. R.G. received support from an NIH NCI-T32 postdoctoral research fellowship. A.G. received support from the Howard Hughes Medical Institute’s Medical Research Fellows Program. R.Z. received support from the Parker Bridge Scholar Award. We thank the Immune Monitoring Core Facility at the Memorial Sloan Kettering Cancer Center for technical assistance.

AUTHOR CONTRIBUTIONS
Conceptualization: S.B., C.A.B., T.M., and J.D.W.; Methodology: S.B., R.Z., S.S., D.H., M.G., L.M., and C.A.B.; Investigation & Resources: R.G., A.G., K.F., R.Z., O.D., S.S., D.H., L.F.C., M.G., C.L., G.M., L.D., and C.A.B.; Formal Analysis: S.B.; Visualization: S.B.; Writing – Original Draft: S.B.; Writing – Review & Editing: R.G., L.F.C., M.G., C.A.B., T.M., and J.D.W.; Supervision & Funding Acquisition: T.M. and J.D.W.

DECLARATION OF INTERESTS
All authors concur with the submission of this manuscript and have no financial or other interests related to the submitted work. T.M. is a cofounder and holds an equity in IMVAQ Therapeutics. He is a consultant of Immunos Therapeutics and Pfizer. He has research support from Bristol Myers Squibb; Surface Oncology; Kyn Therapeutics; Infinity Pharmaceuticals, Inc.; Peregrine Pharmaceuticals, Inc.; Adaptive Biotechnologies; Leap Therapeutics, Inc.; and Aprea. He has patents on applications related to work on oncolytic viral therapy, alpha virus–based vaccine, neoantigen modeling, CD40, GITR, OX40, T-cell killing. Oncotarget, 13 (1), 1–14.

REFERENCES
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Mauri, M.C., Ulrich, E., Saulnier, P., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059.

BELZIE, O., HUANG, X., GONG, J., CARLSON, J., SCHROIT, A.J., BREKKEN, R.A., and FREIMARK, B.D. (2018). Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. ImmuNoTargets Ther. 7, 1–14.

BIRGE, R.B., BOELTZ, S., KUMAR, S., CARLSON, J., WANDERLEY, J., CALLANES, D., BARCINSKI, M., BREKKEN, R.A., HUANG, X., HUTCHINS, J.T., et al. (2016). Phosphatidylserine is a global immunosuppressive signal in effectorcytosis, infectious disease, and cancer. Cell Death Differ. 23, 962–978.

BUDDH, S., LOIKE, J.D., PANDOLFI, A., HAN, S., CATALANO, G., CONSTANTINESCU, A., CLYNES, R., AND SILVERSTEIN, S.C. (2010). CD8+ T cell concentration determines their efficiency in killing cognate antigen-presenting syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 207, 223–235.

CAMPHAUSEN, K., MOSES, M.A., MENARD, C., SPROULL, M., BEECKEN, W.D., FOLKMAN, J., AND ORRELLY, M.S. (2003). Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 63, 1990–1993.

CHEN, H.Y., LU, L., LI, L.F., LU, X.X., GAO, J.X., AND BAI, Y.R. (2018). Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Sci. Rep. 8, 11934.

DAI, P., WANG, W., YANG, N., SENA-TAMAYO, C., RICCA, J.M., ZAMARIN, D., SHUMAN, S., MERGHOUB, T., WOLCHOK, J.D., AND DENG, L. (2017). Intratumoral delivery of inactivated modified vaccinia virus Ankara (MVA) induces systemic antitumor immunity via STING and Batf-3-dependent dendritic cells. Sci. Immunol. 2, eaal1713.

DE GROOT, P.G., AND URBAUS, R.T. (2012). The significance of autoantibodies against i2-glycoprotein I. Blood 120, 266–274.

DENG, L., LIANG, P., BURNETTE, B., BECKETT, M., DARGA, T., WEICHSELBAUM, R.R., AND FU, Y.X. (2014). Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695.

DIAMOND, J.M., VANPOULLE-BOX, C., SPADA, S., RUDQVIST, N.P., CHAPMAN, J.R., UEBERHEIDE, B.M., PILONES, K.A., SARFRAY, F., FORMENTI, S.C., AND DEMARIA, S. (2018). Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol. Res. 6, 910–920.

FORMENTI, S.C., RUDQVIST, N.P., GOLDEN, E., COOPER, B., WENNERBERG, E., LHUILIER, C., VANPOULLE-BOX, C., FRIEDMAN, K., FERRARI DE ANDRADE, L., WUCHERPLenig, K.W., et al. (2018). Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851.

FREIMARK, B.D., GONG, J., YE, D., GRAY, M.J., NGUYEN, V., YIN, S., SCHATZ, H.M., HUGHES, C.C., SCHROIT, A.J., HUTCHINS, J.T., et al. (2016). Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. Cancer Immunol. Res. 4, 531–540.

GAMEIRO, S.R., JAMMHE, M.L., WATTENBERG, M.M., TANG, K.Y., FERRENO, S., AND HODGE, J.W. (2014). Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5, 403–416.

GERBER, D.E., STOPPECK, A.T., WONG, L., ROSEN, L.S., THORPE, P.E., SHAN, J.S., AND IBRAHIM, N.K. (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17, 6888–6896.

GOLDEN, E.B., DEMARIA, S., SCHIFF, P.B., CHACHOUA, A., AND FORMENTI, S.C. (2013). An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365–372.

Graham, D.K., DeRYCKERE, D., DAVIES, K.D., AND EARP, H.S. (2014). The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14, 769–785.

GRAY, M.J., GONG, J., HATCH, M.M., NGUYEN, V., HUGHES, C.C., HUTCHINS, J.T., AND FREIMARK, B.D. (2016). Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell check-point inhibition in murine triple-negative breast cancers. Breast Cancer Res. 18, 50.

GUPTA, A., PROBST, H.C., VUONG, V., LANDSHAMMER, A., MUTH, S., YAGITA, H., SCHWENDNER, R., PRUSCHY, M., KRUTH, A., AND VAN DEN BROEK, M. (2012). Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189, 558–566.

Received: July 18, 2019
Revised: June 23, 2020
Accepted: December 18, 2020
Published: January 12, 2021
He, J., Yin, Y., Luster, T.A., Watkins, L., and Thorpe, P.E. (2009). Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin. Cancer Res. 15, 6871–6880.

Hiniker, S.M., Chen, D.S., Reddy, S., Chang, D.T., Jones, J.C., Mollick, J.A., Swetter, S.M., and Knox, S.J. (2012). A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5, 404–407.

Huang, X., Bennett, M., and Thorpe, P.E. (2005). A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res. 65, 4408–4416.

Kumar, S., Calianese, D., and Birge, R.B. (2017). Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment. Immuno Rev. 280, 149–164.

Lee, Y., Ahn, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009). Therapeutic effects of ablative radiation on local tumor require CDB+ T cells: changing strategies for cancer treatment. Blood 114, 589–595.

Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., and Lord, E.M. (2005). Local radiation therapy of B16 melanoma tumors increases the induction of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516–7523.

Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T.O., Babb, J.S., Schneider, R.J., Formenti, S.C., Dustin, M.L., and Demaria, S. (2008). Radiation-induced CXCL16 release by breast cancer cells differentially modulates the abscopal effect in a patient with melanoma. N. Engl. J. Med. 358, 925–931.

Ran, S., He, J., Huang, X., Soares, M., SCOOTH, D., and Thorpe, P.E. (2005). Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin. Cancer Res. 11, 1551–1562.

Rizzuto, G.A., Merghoub, T., Hirschhorn-Cymerman, D., Liu, C., Lesokhin, A.M., Sahawneh, D., Zhong, H., Panagreas, K.S., Perales, M.A., Altan-Bonnet, G., et al. (2009). Self-antigen-specific CDB+ T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 206, 849–866.

Rodriguez-Ruiz, M.E., Rodriguez, I., Garasa, S., Barbes, B., Solorzano, J.L., Perez-Gracia, J.L., Labiano, S., Sanmamed, M.F., Azpilikueta, A., Bolahos, E., et al. (2016). Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Res. 76, 5984–6005.

Sauer, J.D., Sotelo-Troha, K., von Moltke, J., Monroe, K.M., Rae, C.S., Brubaker, S.W., Hyodo, M., Hayakawa, Y., Woodward, J.J., Portnoy, D.A., and Vance, R.E. (2011). The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688–694.

Sharma, B., and Kanwar, S.S. (2018). Phosphatidylserine: A cancer cell targeting biomarker. Semin. Cancer Biol. 52, 17–25.

Siva, S., MacManus, M.P., Martin, R.F., and Martin, O.A. (2019). Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 356, 82–90.

Stamell, E.F., Wolchok, J.D., Gnajtic, S., Lee, N.Y., and Brownell, I. (2013). The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85, 293–295.

Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benc, J.I., Xu, B., Dada, H., Odorizzi, P.M., et al. (2015). Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377.

Vanpoille-Box, C., Alard, A., Aryankalayar, M.J., Sarazin, Y., Diamond, J.M., Schneider, R.J., Inghirami, G., Coleman, C.N., Formenti, S.C., and Demaria, S. (2017). DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618.

Yin, Y., Huang, X., Lynn, K.D., and Thorpe, P.E. (2013). Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol. Res. 1, 256–268.

Zappasodi, R., Budh, S., Heilmann, M.D., Postow, M.A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., LI, Y., et al. (2018a). Non-conventional Inhibitory CD4+Foxp3+PD-1+ T Cells as a Biomarker of Immunological Checkpoint Blockade Activity. Cancer Cell 33, 1017–1032.e7.

Zappasodi, R., Merghoub, T., and Wolchok, J.D. (2018b). Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell 34, 690.
## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| Mouse mch1N11 (PS targeting antibody) | Oncologie | N/A |
| Mouse isotype control (clone C44) | Oncologie | N/A |
| Mouse anti-PD1 (clone RMP1-14) | Bioxcell | Cat# BE0146, RRID:AB_10949053 |
| Mouse anti-CD8 (clone 2.43) | Bioxcell | Cat# BE0061, RRID:AB_1125541 |
| Mouse CD8a MicroBeads | Miltenyi Biotech | Cat# 130-117-044 |
| mouse Fc-block (clone 2.4G2) | MSKCC Antibody core | N/A |
| human Fc-block | Miltenyi Biotech | Cat# 130-059-901 |
| anti-PS, Alexa Flour 488 (clone 1H6) | Millipore - Sigma | Cat# 16-256, RRID:AB_492616 |
| Anti-CD8 PE-Texas Red | ThermoFisher Scientific | Cat# MCD0817, RRID:AB_1488461 |
| Anti-CD8 PE-Cy7 | BD Biosciences | Cat# 557654, RRID:AB_396769 |
| Anti-CD8 PE | BD Biosciences | Cat# 553033, RRID:AB_394571 |
| Anti-Ly6G Percp-Cy5.5 | BD Biosciences | Cat# 560602, RRID:AB_1727563 |
| Anti-Ly6C PE-Cy7 | BD Biosciences | Cat# 560593, RRID:AB_1727557 |
| Anti-CD4 V450 | BD Biosciences | Cat# 560468, RRID:AB_1645271 |
| Anti-CD11c APC | BD Biosciences | Cat# 550261, RRID:AB_398460 |
| Anti-CD11c FITC | BD Biosciences | Cat# 557400, RRID:AB_396683 |
| Anti-CD45 Alexa Flour 700 | eBioscience | Cat# 56-0451-82, RRID:AB_891454 |
| Anti-CD11b APC-Cy7 | BD Biosciences | Cat# 557657, RRID:AB_396772 |
| Anti-CD11b Alexa Flour 700 | Biolegend | Cat# 101222, RRID:AB_493705 |
| Anti- MHC Class II (I-A/I-E) eFluor 450 | eBioscience | Cat# 48-5321-82, RRID:AB_1272204 |
| Anti-F4/80 BV650 | Biolegend | Cat# 123149, RRID:AB_2564589 |
| Anti-CD206 PE | Biolegend | Cat# 141706, RRID:AB_10895754 |
| Anti-CD206 Alexa Flour 647 | Biolegend | Cat# 141712, RRID:AB_10900420 |
| Anti- Ki67 FITC | eBioscience | Cat# 11-5698-82, RRID:AB_1151330 |
| Anti-CD62L Percp-Cy5.5 | eBioscience | Cat# 45-0621-82, RRID:AB_996667 |
| Anti-PD-1 PE-Cy7 | eBioscience | Cat# 25-9985-82, RRID:AB_10853805 |
| Anti-Foxp3 APC | eBioscience | Cat# 17-5773-82, RRID:AB_469457 |
| Anti-Foxp3 FITC | eBioscience | Cat# 11-5773-82, RRID:AB_465243 |
| Anti-CD44 APC-Cy7 | Biolegend | Cat# 103028, RRID:AB_830785 |
| Anti-CD44 V450 | BD Biosciences | Cat# 560451, RRID:AB_1645273 |
| Anti-Thy1.1 APC | BD Biosciences | Cat# 561409, RRID:AB_10683163 |
| Anti-T-bet Percp-Cy5.5 | eBioscience | Cat# 45-5825-82, RRID:AB_953657 |
| Anti-CD3 Percp-Cy5.5 | BD Biosciences | Cat# 561108, RRID:AB_10562558 |
| Anti-CD3 APC-Cy7 | BD Biosciences | Cat# 557596, RRID:AB_396759 |
| Anti-IFNγ Percp-Cy5.5 | eBioscience | Cat# 45-7311-82, RRID:AB_1107020 |
| Anti-TNFα PE-Cy7 | BD Biosciences | Cat# 557644, RRID:AB_396761 |
| Human Anti-Granzyme B PE-Texas Red | ThermoFisher Scientific | Cat# GRB17, RRID:AB_1500187 |
| Human Anti-CD3 PE-Texas Red/ECD | Beckman Coulter | Cat# IM2705U, RRID:AB_130860 |
| Human Anti-CD4 Percp-Cy5.5 | eBioscience | Cat# 45-0048-42, RRID:AB_10804390 |
| Human Anti-CD56 PE-Cy7 | BD Biosciences | Cat# 335809, RRID:AB_399984 |
| Human Anti-CD8a Pacific Blue | BD Biosciences | Cat# 558027, RRID:AB_397058 |
| Human Anti-CD4 APC-Cy7 | ThermoFisher Scientific | Cat# A15453, RRID:AB_2534466 |

(Continued on next page)
### REAGENT or RESOURCE SOURCE IDENTIFIER

**Chemicals, Peptides, and Recombinant Proteins**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| GMSCF               | Preprotech, Inc | Cat# 315-03 |
| PMA                 | Sigma-Aldrich | Cat# P8139 |
| Ionomycin           | Sigma-Aldrich | Cat# I0634 |
| Monensin            | Sigma-Aldrich | Cat# M5273 |
| Brefeldin A         | BD biosciences | Cat# 555029 |
| TRizol Reagent      | Invitrogen | Cat# 15596018 |
| Annexin V - PE      | eBioscience | Cat# 556421 |
| Annexin V binding buffer | eBioscience | Cat# 556454 |
| Caspase 3/7 green   | ThermoFisher Scientific | Cat# C10423 |
| Fixable Viability Dye eFluor 506 | ThermoFisher Scientific | Cat# 65-0866-14 |
| Percoll             | Cytiva (GE Healthcare) | Cat# 17089101 |
| Cellstripper        | Corning | Cat# 25-056-CI |
| Foxp3 / Transcription Factor Staining Buffer Set | eBioscience | Cat# 00-5523-00 |
| ACK lysis Buffer    | Lonza | Cat# 10-548E |

**Experimental Models: Cell Lines**

| Cell Lines | SOURCE | IDENTIFIER |
|------------|--------|------------|
| B16F10     | I. Fidler (MD Anderson) | N/A |
| MC38       | Kerafast, Inc. | Cat# ENH204-FP |
| B16F10 Sting<sup>−/−</sup> | Generated in lab | N/A |

**Experimental Models: Organisms/Strains**

| Organisms/Strains | SOURCE | IDENTIFIER |
|-------------------|--------|------------|
| Mouse; C57BL/6J   | Jackson Laboratory | Stock # 000664 |
| Mouse Pmel TCR transgenic | Bred in house | N/A |
| Mouse: Sting<sup>−/−</sup> (Tmem173<sup>−/−</sup>) | Jackson Laboratory | Stock # 017537 |

**Oligonucleotides**

| Oligonucleotides | SOURCE | IDENTIFIER |
|------------------|--------|------------|
| Arg1             | ThermoFisher Scientific | Mm00475988_m1 |
| CCL2 (MCP1)      | ThermoFisher Scientific | Mm00436439_m1 |
| CCL22            | ThermoFisher Scientific | Mm00436439_m1 |
| CD11b            | ThermoFisher Scientific | Mm00434455_m1 |
| CD206 (Mrc1)     | ThermoFisher Scientific | Mm01329362_m1 |
| CD4              | ThermoFisher Scientific | Mm00442754_m1 |
| CD8              | ThermoFisher Scientific | Mm01182107_g1 |
| GMCSF (CSF2)     | ThermoFisher Scientific | Mm09999009_m1 |
| CXCL12 (SDF1)    | ThermoFisher Scientific | Mm00445552_m1 |
| FAP<sub>x</sub>  | ThermoFisher Scientific | Mm00484254_m1 |
| FasL              | ThermoFisher Scientific | Mm00438864_m1 |
| Foxp3            | ThermoFisher Scientific | Mm00475156_m1 |
| GARP (Lnc32)     | ThermoFisher Scientific | Mm01273954_m1 |
| Granzyme B       | ThermoFisher Scientific | Mm00442834_m1 |
| IDO              | ThermoFisher Scientific | Mm00492586_m1 |
| IFNβ             | ThermoFisher Scientific | Mm00439552_s1 |
| IFNγ             | ThermoFisher Scientific | Mm00801778_m1 |
| IL10             | ThermoFisher Scientific | Mm00439616_m1 |
| IL15             | ThermoFisher Scientific | Mm00434210_m1 |
| IL1α             | ThermoFisher Scientific | Mm00439620_m1 |
| IL1β             | ThermoFisher Scientific | Mm00434228_m1 |
| IL2              | ThermoFisher Scientific | Mm00434256_m1 |
| IL4R<sub>x</sub> | ThermoFisher Scientific | Mm00439634_m1 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Taha Merghoub (merghout@mskcc.org).

Materials Availability
This study did not generate new unique reagents.

Data and Code Availability

- Original/source data for [figures/datatype] in the paper are available from the corresponding authors on request.

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| IL6                 | ThermoFisher Scientific | Mm00446190_m1 |
| CXCL10 (IP-10)      | ThermoFisher Scientific | Mm0045235_m1 |
| ItgaV               | ThermoFisher Scientific | Mm01302428_m1 |
| CCL8 (MCP-2)        | ThermoFisher Scientific | Mm01297183_m1 |
| MHC I               | ThermoFisher Scientific | Mm01612247_m1H |
| MHC II              | ThermoFisher Scientific | Mm00439216_m1 |
| CXCL9 (Mig)         | ThermoFisher Scientific | Mm00434946_m1 |
| CCL3 (MIP1a)        | ThermoFisher Scientific | Mm00441258_m1 |
| CCL4 (MIP-1b)       | ThermoFisher Scientific | Mm00443111_m1 |
| CXCL2 (MIP2a)       | ThermoFisher Scientific | Mm00436450_m1 |
| PDL1                | ThermoFisher Scientific | Mm00452054_m1 |
| Perforin 1          | ThermoFisher Scientific | Mm004812512_m1 |
| Rae1                | ThermoFisher Scientific | Mm00558293_g1 |
| CCL5 (Rantes)       | ThermoFisher Scientific | Mm01302428_m1 |
| STAT1               | ThermoFisher Scientific | Mm00439518_m1 |
| TGFβ1               | ThermoFisher Scientific | Mm01178820_m1 |
| TGFβ2               | ThermoFisher Scientific | Mm00436955_m1 |
| TGFβ3               | ThermoFisher Scientific | Mm00436960_m1 |
| TNFα                | ThermoFisher Scientific | Mm00443258_m1 |
| VEGF                | ThermoFisher Scientific | Mm00437304_m1 |
| Gapdh               | ThermoFisher Scientific | Mm00607939_g1 |
| Actb                | ThermoFisher Scientific | Mm00607939_s1 |

Software and Algorithms

- Prism 7: GraphPad Software, LLC (online download) https://www.graphpad.com/scientific-software/prism/
- FlowJo v.10: FlowJo, LLC (online download) https://www.flowjo.com/solutions/flowjo/downloads
- Microsoft Excel: Microsoft Inc N/A
- Microsoft Word: Microsoft Inc N/A
- Microsoft Powerpoint: Microsoft Inc N/A

Other

- MACS LS columns: Miltenyi Biotech Cat# 130-042-401
- MidiMACS Separator: Miltenyi Biotech Cat# 130-042-302
- MACS MultiStand: Miltenyi Biotech Cat# 130-042-303
- Animal X-ray irradiator: Precision X-Ray Model: X-RAD 320
- Biomark HD system: Fluidigm Cat# BMKHD
- 48.48 Dynamic Array IFC: Fluidigm Cat# BMK-M-48.48
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse Models
Female C57BL/6J mice (8-10 weeks) were purchased from the Jackson Laboratory (Bar Harbor, ME). Breeding pairs for Pmel-1 TCR transgenic mice (Overwijk et al., 2003) were obtained from N. Restifo (National Institutes of Health). Sting<sup>GR</sup> mice in C57BL/6J background was generated in Dr. Russell Vance’s laboratory (University of California, Berkeley) (Sauer et al., 2011). We obtained breeding pairs of the C57BL/6 Sting<sup>GR</sup> from Liang Deng’s lab at MSK (Dai et al., 2017). For Pmel and Sting<sup>GR</sup> mice, both male and female mice (8-10 weeks old) were used for experiments. Mouse experiments were performed in accordance with institutional guidelines under a protocol approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee. All mice were maintained in a pathogen-free facility according to National Institutes of Health Animal Care guidelines.

Cell lines
The B16F10 mouse melanoma line was originally obtained from I. Fidler. The B16F10 Sting<sup>-/-</sup> cell line was generated using CRISPR/Cas9 and confirmed by western blotting. MC38 cell line was purchased from Kerafast, Inc. These cells were maintained in RPMI-1640 medium containing 7.5% fetal bovine serum (FBS) and L-glutamine. Cells were detached using 0.25% trypsin/EDTA. For cell surface staining and CD8+ T cell killing assays, cells were detached non-enzymatically using Cellstripper or 5mM EDTA.

Patient Material
All patients signed an approved informed consent before providing tissue samples. Patient samples were collected on a tissue-collection protocol approved (06-107) by the MSK Institutional Review Board. Human peripheral blood was collected from 7 patients (male and female) with metastatic cutaneous melanoma prior to and 4-7 days after receiving tumor-directed RT (27 Gy in 3 fractions of 9 Gy) to one or more sites of metastases. PBMCs were isolated from whole blood by the MSK Immune Monitoring Core Facility.

METHOD DETAILS

In vivo mouse experiments with tumor-directed RT and monoclonal antibody treatment
8-10 week old C57BL/6 female mice were injected intradermally on the right hindlimb with 100,000 B16F10 cells in 50 μL of PBS. On day 7-10, when tumors reached ~50mm² in size, mice were anesthetized with isoflurane and placed in a radiation jig where only the hindlimb is exposed (Camphausen et al., 2003). The right hindlimb was irradiated with 15 Gy RT using the X-RAD 320 focus beam irradiator such that only the exposed hindlimb bearing the tumors will receive radiation. On days 1 and 4 after RT, each mouse received intraperitoneal injections (i.p.) of 0.2mg of the phosphatidylserine-targeting antibody (mch1N11) in 0.2ml of PBS. In experiments where anti-PD-1 was given, mice received 0.25mg of anti-PD-1 (clone RMP1-14) i.p. in 0.2ml of PBS on days 1, 4, and 7 after RT. For tumor measurements, each mouse was tagged by ear notching on day 5 post tumor implantation and tumor size (length and width) was measured every 3-4 days using a caliper for the duration of the experiment. Tumor measurements (surface area in mm²) and overall survival were used to determine efficacy of the treatments.

For the bilateral tumor model, C57BL/6 mice (10 mice/group) were injected with 100,000 B16F10 melanoma cells intradermally on the right hindlimb. 5 days later, the same animals were injected with 100,000 B16F10 melanoma cells intradermally on the left flank (for abscopal tumors). On day 10 post tumor implantation, mice were treated with a single dose of 15Gy RT on the right hindlimb. On days 11 and 14, mice were injected i.p. with 200 μg/mouse of mch1N11 or without 250 μg/mouse (given every 3 days for a total of 3 days).

CD8+ T cells were depleted by i.p. injection of 200 μg of a depleting antibody (clone 2.43) starting the same day as RT and given every 3 days thereafter until the end of the experiment.

Gene expression in ex vivo tumors
C57BL/6 mice (3-5 mice/group) were injected with 100,000 B16F10 melanoma cells on the right hindlimb and treated with RT and one dose of mch1N11 as described above. Tumors were harvested 3 days after initial treatment. RNA was extracted from whole tumors and analyzed for gene expression of 43 pro- and anti-inflammatory genes that were selected based on our in-house collection of pre-optimized mouse Taqman probes (see Key Resources Table and Table S1). Tumor samples (5 mice/group) were analyzed on a 48.48 Dynamic Array integrated fluidic circuit (IFC) for Gene Expression on the Fluidigm Biomark MX/HD as per manufacturer’s protocol. Gene expression data are represented as the average fold change (2<sup>ΔΔCT</sup>) relative to the control group (Figure 3F) or normalized to GAPDH (Figure S2).

Adoptive transfer of Pmel CD8+ T cells
C57BL/6 mice (5 mice/group) were injected with 100,000 B16F10 melanoma cells on the right hindlimb. On day 10 post tumor implantation, mice were treated with a single dose of 15Gy RT on the hindlimb. Naive CD8+ T cells were purified from spleens of Pmel-1 TCR transgenic mice by magnetic-activated cell sorting (MACS) and fluorescently labeled with 1μM CFSE as previously described (Rizzuto et al., 2009). On the same day as RT (day 10), each mouse received 10<sup>6</sup> CFSE-labeled Pmel CD8+ T cells by tail vein injection. One day after RT (day 11), mice were injected i.p. with 200 μg/mouse of mch1N11 or isotype control. Blood, spleens, draining inguinal
LNs and tumors were excised 7 days after RT (day 17) and dissociated into single cell suspensions for analysis by flow cytometry. Pmel CD8+ T cells were identified by staining for the congenic marker Thy1.1.

**In vitro macrophage polarization**

Bone marrow (BM) from naïve C57BL/6 mice were isolated and cultured in 60cm Petri dishes at 5x10⁶ cells in 5 mL of complete media (RPMI with 10% fetal bovine serum (FBS) supplemented with 2mL L-glutamine, 1mM sodium pyruvate and 50 mM 2-mercaptoethanol) in the presences of 20ng/ml recombinant murine GMCSF. Cultures were fed every 2 days with fresh medium containing GMCSF. After 6 days in culture, BM cells were detached non-enzymatically using cell scrapers and re-plated in 12-well plates containing 1ml of complete medium with 5% mouse serum and 10⁶ BM cells per well in the presence or absence of an isotype control (C44) or PS-targeting (mch1N11) antibody. 24 hours later, cells were detached and analyzed by flow cytometry for APCs (CD11c+, MHC II+), total macrophages (CD11b+ F4/80+), M1 (MHC II+ CD206-) and M2 (MHC II- CD206+) macrophages.

**Flow Cytometry of mouse LNs, spleens, and tumors**

Cells from tumor draining LNs, spleens, and tumors were prepared by mechanical dissociation in 40 μM filters and red blood cells were removed from spleens and blood using ACK lysis buffer. When tumor weight was greater than 0.1 g, cells were purified using a 40% Percoll gradient centrifugation. For staining for flow cytometry analysis: 100 μL of single cell suspensions of each tissue were plated in 96-well round bottom plates. Cells were pelleted by spinning at 2,000 rpm for 5 mins. Cells were incubated in 100 μL of 5 μg/ml Fc-block antibody (clone 2.4G2) for 20 mins on ice in FACS buffer (PBS + 0.5% BSA + 2mM EDTA). After Fc-block, cells were stained in FACS buffer containing fluorophore conjugated surface antibodies and a fixable viability dye for 20 mins on ice, then washed 2 times with 200 μL FACS buffer. All intracellular staining was conducted using the Foxp3 fixation/permeabilization buffer according to the manufacturer’s instructions. Flow cytometry was performed on a BD LSRII or Cytek Aurora. FlowJo software V10 was used for all flow cytometry analysis.

For intracellular cytokine staining, single cell suspensions of tissues were plated in 96-well round bottom plates containing 200 μL complete medium with 1 μM PMA and 1 μM Ionomycin. Plates were incubated for 30 mins at 37°C, then Brefeldin A (1:1000 dil) and 10 μg/ml Monensin was added and incubated for an additional 5 hr at 37°C. The plates were chilled at 4°C and stained for intracellular cytokine and analyzed by flow cytometry.

**Annexin V and Caspase 3/7 staining of mouse tissues**

C57BL/6 mice (6 mice/group) were injected with 100,000 B16F10 melanoma cells intradermally on the hindlimb, 10 days later, tumors were treated with a single dose of 15 Gy RT. Tumors were excised 1, 5 and 10 days after RT and processed for flow cytometry. 100 μL of single cell suspensions of each tissue were plated in 96-well round bottom plates. Cells were pelleted by spinning at 2,000 rpm for 5 mins. Cells were incubated in 100 μL of complete medium containing 2 μM Caspase-3/7 Green Detection Reagent and incubated at 37°C for 30 mins. Cells were chilled, pelleted and washed once with 200 μL Annexin V Binding buffer. Cells were incubated in 100 μL of 5 μg/ml Fc-block antibody (clone 2.4G2) for 20 mins on ice in Annexin V Binding buffer. Cells were pelleted then incubated at room temperature for 20 mins in the dark with 100 μL of Annexin V Binding buffer containing Annexin V-PE or anti-PS-Alexa Fluor 488 (clone 1H6), a viability dye and fluorophore conjugated cell surface antibodies. Cells were washed twice with 200 μL Annexin V Binding buffer and then analyzed by flow cytometry.

**Annexin staining of melanoma patients PBMCs**

Freshly isolated PBMCs from each patient were stained for PS expression using Annexin V and caspase 3/7 on the day the same day blood was collected. 1x10⁶ PBMCs were plated in 96-well round bottom plates. Cells were incubated in 100 μL of complete medium containing 2 μM Caspase-3/7 Green Detection Reagent and incubated at 37°C for 30 mins. Cells were pelleted and washed once with 200 μL Annexin V Binding buffer. Cells were incubated in 50 μL of human Fc-block for 20 mins on ice in FACS buffer. Cells were pelleted then incubated on ice for 20 mins with 100 μL of FACS buffer containing fluorophore conjugated cell surface antibodies. Cells were washed twice with 200 μL Annexin V Binding buffer and the incubated in 100 μL of Annexin V Binding buffer containing Annexin V-PE or anti-PS-Alexa Fluor 488 for 20 mins at room temperature in the dark. Cells were washed twice with 200 μL Annexin V Binding buffer and then analyzed by flow cytometry.

**CD8+ T cell killing assay**

Single cell suspensions of splenocytes were isolated from treated animals and CD8+ T cells were purified using the MACS beads according to the manufacturer’s protocol. 1mL complete medium containing 10⁶ CD8+ T cells and 10⁶ B16 tumor cells (as targets) were added to 24-well plates and incubated for 48h at 37°C. The T cells were washed away with 1mL PBS and the remaining viable tumor cells were detached using 0.25% Trypsin/EDTA. The detached tumor cells were diluted and plated in six-well plates for colony formation. Seven days later, plates were fixed with 3.7% formaldehyde and stained with 2% methylene blue as previously described (Budhu et al., 2010). Colonies were counted manually to assess number of viable cells.
QUANTIFICATION AND STATISTICAL ANALYSIS

Unless otherwise indicated, p values were calculated using a 2-tailed Student’s t test or two-way ANOVA-test corrected for multiple comparisons. A p value of < 0.05 was considered statistically significant. Overall survival curves and median survival (days) of each treatment group was obtained from pooled replicate experiments and analyzed using Kaplan–Meier estimator. The survival curves measure time from start of experiment to tumor diameter of 2cm (in which case the mouse needs to be euthanized) or death. However, the tumor volume curves averaged at each time point per group are only reported for as long as all mice in a group are alive. p values comparing survival curves were calculated using the Log-rank (Mantel-Cox) test. Correlations of T cell frequencies with tumor weight were done using Pearson’s correlation.

All graphs and statistical calculations were done using GraphPad Prism software and Microsoft Excel.
Supplemental Information

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

Sadna Budhu, Rachel Giese, Aditi Gupta, Kelly Fitzgerald, Roberta Zappasodi, Sara Schad, Daniel Hirschhorn, Luis Felipe Campesato, Olivier De Henau, Mathieu Gigoux, Cailian Liu, Gregory Mazo, Liang Deng, Christopher A. Barker, Jedd D. Wolchok, and Taha Merghoub
Figure S1. Mechanisms of PS increase after RT.

Related to Figure 1

A

CD11b DCs

FMO

No RT

+ RT

Annexin V PE  Anti-PS FITC

B

Annexin V PE

Anti-PS FITC

C

Day 1

Day 5

D

In vitro

E

No RT

15 Gy RT

CD8 depletion

F

WT mice

CD8 depleted

Sting<sup>Gt/Gt</sup> mice

G

Control

RT

% of CD45+

CD4 T cells

CD8 T cells

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Other immune cells

Control: RT

% of CD45+

0

20

40

60

80

100

Annexin V+ cells

PS+ cells

Annexin V+ cells

CD4

CD8

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Tumor

Annexin V+ cells

CD4

CD8

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Tumor

Annexin V+ cells

CD4

CD8

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Tumor

Annexin V+ cells

CD4

CD8

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Tumor

Annexin V+ cells

CD4

CD8

Monocytes

Neutrophils

Macrophages

CD8 DCs

CD11b APCs

Other APCs

Tumor
Figure S2. Targeting PS with mch1N11 promotes a pro-inflammatory tumor microenvironment.

Related to Figure 3

Pro-inflammatory cytokines

Anti-inflammatory markers

*p<0.05, **p<0.01, ***p<0.005.
Figure S3. RT + mch1N11 increases T cell activation and priming.
Related to Figure 4

A

Heatmap of T cell activation markers

B

**p<0.01, ***p<0.005.
Figure S4: Targeting PS enhances the anti-tumor activity of radiation and anti-PD-1 in Sting<sup>Gt/Gt</sup> mice and in MC38 colon carcinoma.

Related to Figure 5

A

Figure A

B

Figure B

C

Figure C

No RT groups

RT groups

Median survival | % tumor free
--- | ---
Control (Naïve) | 27 | 0%
aPS | 26 | 0%
aPS+ | 26 | 0%
aPS+aPD1 | 24 | 0%
RT | 22 | 0%
RT+aPS | 24 | 0%
RT+ | 24 | 0%
RT+aPD1 | 24 | 0%
RT+aPS+aPD1 | 24 | 0%

*<sup>p</sup><0.05, **<sup>p</sup><0.01, ***<sup>p</sup><0.005.
Figure S5: Triple combination therapy enhances systemic T cell activation in the spleen and draining LN.

Related to Figure 6

A  Spleen  

|            | CD8 T cells | CD4 T cells |
|------------|-------------|-------------|
|            | Control     | mch1N11     | aPD1       | mch1N11 + aPD1 |
| CD8+ T cells |             |             |            |               |
| No RT      |             |             |            |               |
| RT         |             |             |            |               |
|            | ***         | ***         | *          |               |

|            | Ki67+ cells | Granzyme B+ cells |
|------------|-------------|-------------------|
| No RT      |             |                   |
| RT         |             |                   |
|            | ***         | **                |

B  LN  

|            | CD8 T cells | CD4 T cells |
|------------|-------------|-------------|
|            | Control     | mch1N11     | aPD1       | mch1N11 + aPD1 |
| CD8+ T cells |             |             |            |               |
| No RT      |             |             |            |               |
| RT         |             |             |            |               |
|            | ***         | ***         | *          |               |

|            | Ki67+ cells | Granzyme B+ cells |
|------------|-------------|-------------------|
| No RT      |             |                   |
| RT         |             |                   |
|            | ***         | **                |

C  

|            | CD4PD1 hi cells | CD4:Treg ratio |
|------------|-----------------|-----------------|
| No RT      |                 |                 |
| RT         |                 |                 |
|            | ***             | **              |

D  

|            | CD4PD1 hi cells | CD8:Treg ratio |
|------------|-----------------|-----------------|
| No RT      |                 |                 |
| RT         |                 |                 |
|            | ***             | **              |

*p<0.05, **p<0.01, ***p<0.005.
Figure S6: Targeting PS in combination with radiation therapy and anti-PD-1 promotes CD8+ T cell activation in the tumor;

Related to Figure 6
Figure S7. Annexin and PS staining in patients’ PBMCs is increased after RT.

Related to Figure 7

A

B

CD14+ Monocytes
CD14- Myeloid cells
CD56+ NK cells
CD56int NK cells
CD4 T cells
CD8 T cells

Annexin V

Anti-PS

C

PBMC PD-1 expression

PD-1

CD56 int NK cells
CD56 hi NK cells
CD8 T cells
CD4 T cells
CD14- Myeloid
CD14+ Monocytes

D

E

Monocytes
Other myeloid cells
CD56int NK cells
CD56high NK cells
CD4 T cells
CD8 T cells

Caspase 3/7

Annexin V

Days post RT

CD14+ Monocytes
CD11b+CD14- Myeloid
CD56 hi-NK
CD56 int
CD4
CD8
Table S1 – List of pre-selected probes used to examine gene expression in tumors
Related to Figure 3 and STAR METHODS: Gene expression in ex vivo tumors

| Marker                  | Function                                      |
|-------------------------|-----------------------------------------------|
| Arg1                    | MDSC enzyme                                   |
| CCL2 (MCP1)             | proinflammatory cytokine                     |
| CCL22                   | proinflammatory cytokine                     |
| CD11b                   | integrin/myeloid marker                      |
| CD206 (Mr1)             | M2 macrophage marker                         |
| CD4                     | CD4 antigen                                   |
| CD8                     | CD8 alpha                                     |
| GMCSF (CSF2)            | proinflammatory cytokine/MDSC                |
| CXCL12 (SDF1)           | proinflammatory cytokine                     |
| FAPα                    | activated fibroblast                          |
| FasL                    | cell death ligand                             |
| Foxp3                   | Treg marker                                   |
| GARP (Lrc32)            | TGFβ processing                               |
| Granzyme B              | cytolytic protein                             |
| IDO                     | MDSC enzyme                                   |
| IFNβ                    | proinflammatory cytokine                     |
| IFNγ                    | proinflammatory cytokine                     |
| IL10                    | immunosuppressive cytokine                   |
| IL15                    | proinflammatory cytokine                     |
| IL1α                    | proinflammatory cytokine                     |
| IL1β                    | proinflammatory cytokine                     |
| IL2                     | proinflammatory cytokine                     |
| IL4Rα                   | chemokine receptor/MDSC                      |
| IL6                     | proinflammatory cytokine                     |
| CXCL10 (IP-10)          | proinflammatory cytokine                     |
| ItgαV                   | TGFβ processing                               |
| CCL8 (MCP-2)            | proinflammatory cytokine                     |
| MHC I                   | MHC class I - H2K                             |
| MHC II                  | MHC class II - I-Ab                           |
| CXCL9 (Mig)             | proinflammatory cytokine                     |
| CCL3 (MIP1a)            | proinflammatory cytokine                     |
| CCL4 (MIP-1b)           | proinflammatory cytokine                     |
| CXCL2 (MIP2a)           | proinflammatory cytokine                     |
| PDL1                    | T cell inhibitory molecule                    |
| Perforin 1              | cytolytic protein                             |
| Rae1                    | NK receptor                                   |
| CCL5 (Rantes)           | proinflammatory cytokine                     |
| STAT1                   | IFN signaling                                 |
| TGFβ1                   | immunosuppressive cytokine                   |
| TGFβ2                   | immunosuppressive cytokine                   |
| TGFβ3                   | immunosuppressive cytokine                   |
| TNFα                    | proinflammatory cytokine                     |
| VEGF                    | pro-angiogenic cytokine                       |

Blue represents pro-inflammatory genes. Red represents anti-inflammatory genes.